213 related articles for article (PubMed ID: 31015615)
1. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy.
Hu Q; Sun W; Wang J; Ruan H; Zhang X; Ye Y; Shen S; Wang C; Lu W; Cheng K; Dotti G; Zeidner JF; Wang J; Gu Z
Nat Biomed Eng; 2018 Nov; 2(11):831-840. PubMed ID: 31015615
[TBL] [Abstract][Full Text] [Related]
2. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
4. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy.
Sanjuan-Pla A; Macaulay IC; Jensen CT; Woll PS; Luis TC; Mead A; Moore S; Carella C; Matsuoka S; Bouriez Jones T; Chowdhury O; Stenson L; Lutteropp M; Green JC; Facchini R; Boukarabila H; Grover A; Gambardella A; Thongjuea S; Carrelha J; Tarrant P; Atkinson D; Clark SA; Nerlov C; Jacobsen SE
Nature; 2013 Oct; 502(7470):232-6. PubMed ID: 23934107
[TBL] [Abstract][Full Text] [Related]
5. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
6. Bioinspired and Biomimetic Nanomedicines.
Chen Z; Wang Z; Gu Z
Acc Chem Res; 2019 May; 52(5):1255-1264. PubMed ID: 30977635
[TBL] [Abstract][Full Text] [Related]
7. CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age.
Gekas C; Graf T
Blood; 2013 May; 121(22):4463-72. PubMed ID: 23564910
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
Poh SL; Linn YC
Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
[TBL] [Abstract][Full Text] [Related]
9. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
10. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Liu J; Yuan Y; Chen W; Putra J; Suriawinata AA; Schenk AD; Miller HE; Guleria I; Barth RJ; Huang YH; Wang L
Proc Natl Acad Sci U S A; 2015 May; 112(21):6682-7. PubMed ID: 25964334
[TBL] [Abstract][Full Text] [Related]
11. Frequency of acute myeloid leukaemia-associated mouse chromosome 2 deletions in X-ray exposed immature haematopoietic progenitors and stem cells.
Olme CH; Brown N; Finnon R; Bouffler SD; Badie C
Mutat Res; 2013 Aug; 756(1-2):119-26. PubMed ID: 23665297
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
Nahas MR; Stroopinsky D; Rosenblatt J; Cole L; Pyzer AR; Anastasiadou E; Sergeeva A; Ephraim A; Washington A; Orr S; McMasters M; Weinstock M; Jain S; Leaf RK; Ghiasuddin H; Rahimian M; Liegel J; Molldrem JJ; Slack F; Kufe D; Avigan D
Br J Haematol; 2019 May; 185(4):679-690. PubMed ID: 30828801
[TBL] [Abstract][Full Text] [Related]
13. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
Sehgal A; Whiteside TL; Boyiadzis M
Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
[TBL] [Abstract][Full Text] [Related]
15. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
16. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen.
Xie X; Hu Y; Ye T; Chen Y; Zhou L; Li F; Xi X; Wang S; He Y; Gao X; Wei W; Ma G; Li Y
Nat Biomed Eng; 2021 May; 5(5):414-428. PubMed ID: 33046865
[TBL] [Abstract][Full Text] [Related]
18. The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.
Lange A; Jaskula E; Lange J; Dworacki G; Nowak D; Simiczyjew A; Mordak-Domagala M; Sedzimirska M
PLoS One; 2018; 13(1):e0190525. PubMed ID: 29304116
[TBL] [Abstract][Full Text] [Related]
19. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
20. PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia.
Xu X; Zhang W; Xuan L; Yu Y; Zheng W; Tao F; Nemechek J; He C; Ma W; Han X; Xie S; Zhao M; Wang J; Qu Y; Liu Q; Perry JM; Jiang L; Zhao M
Nat Cell Biol; 2023 Jan; 25(1):170-182. PubMed ID: 36624186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]